The TIBO-site on HIV-1 reverse transcriptase represents a new target for anti-HIV chemotherapy

Rudi Pauwels; Zeger Debyser; Koen Andries; Mitsuo Baba; Dominique Schols; Michael J. Kukla; Jan Desmyter; Paul A. J. Janssen; De Clercq Erik

doi:10.1016/0166-3542(91)90164-m

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article1991

New antiviral target on HIV-1 reverse transcriptase revealed by TIBO derivatives

Zeger Debyser, Rudi Pauwels, K Andries, Jan Desmyter, Michael J. Kukla, Paj Janssen, De Clercq Erik

Article2010

Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy

Zhao‐Sen Zeng, Qiuqin He, Yonghong Liang, Xiaoqing Feng, Fen‐Er Chen, De Clercq Erik, Jan Balzarini, Christophe Pannecouque

Article1991

Selective inhibitory effect of a TIBO compound, R82150, on the activity of HIV-1 reverse transcriptase

Ono K, Hideo Nakane, Rudi Pauwels, Zeger Debyser, K Andries, Patricia A. Janssen, De Clercq Erik

Article1991

Site-directed mutagenesis of HIV-1 reverse transcriptase

K De Vreese, Zeger Debyser, Rudi Pauwels, De Clercq Erik, Jan Desmyter, Jozef Anné

Article2004

The amino acid N136 in HIV-1 reverse transcriptase qualifies as a target for new (NNRTI) drug design

Jan Balzarini, Johan Auwerx, Fátima Rodrı́guez-Barrios, Francesca Ceccherini‐Silberstein, Carlos Garcı́a-Aparicio, Sonsoles Velázquez, De Clercq Erik, Carlo Federico Perno, Marı́a-José Camarasa, Federico Gago